HAV

Humacyte Announces Presentations by Ukrainian Surgeons on Use of the Human Acellular Vessel™ to Treat Wartime Vascular Trauma at the European Society for Vascular Surgery Annual Meeting

Retrieved on: 
Friday, September 23, 2022

Trauma to the extremities makes up the majority of injuries, primarily vascular injuries to the lower extremities and shoulders.

Key Points: 
  • Trauma to the extremities makes up the majority of injuries, primarily vascular injuries to the lower extremities and shoulders.
  • Shaprynskyi and Sokolov reported that surgeons in Ukraine have utilized the HAV to treat patients with a multitude of wartime injuries.
  • The HAV has received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.
  • Human Acellular Vessels (HAV) are investigational engineered off-the-shelf replacement vessels initially being developed for vascular repair, reconstruction and replacement.

AIM Vaccine Announces Proposed Listing on the Main Board of SEHK

Retrieved on: 
Friday, September 23, 2022

According to CIC, AIM Vaccine is the only China-based vaccine player that has all five proven human vaccine platform technologies worldwide, namely bacterial vaccine technologies, viral vaccine technologies, genetically engineered vaccine technologies, combination vaccine technologies and mRNA vaccine technologies, with at least one approved product or one vaccine candidate at CTA or clinical stages under each platform.

Key Points: 
  • According to CIC, AIM Vaccine is the only China-based vaccine player that has all five proven human vaccine platform technologies worldwide, namely bacterial vaccine technologies, viral vaccine technologies, genetically engineered vaccine technologies, combination vaccine technologies and mRNA vaccine technologies, with at least one approved product or one vaccine candidate at CTA or clinical stages under each platform.
  • AIM Vaccine currently commercializes eight vaccine products against six disease areas, of which the HBV vaccines and human rabies vaccine are its market-leading key commercialized vaccine products.
  • AIM Vaccine acquired Rong'an Bio, AIM Honesty, AIM Kanghuai and AIM Weixin between 2015 and 2017, together with their vaccine products against human rabies, HBV, HAV, mumps and HFRS.
  • AIM Vaccine has leading scientists joining or collaborating with AIM Vaccine to support the Group's vaccine development and manufacturing.

Humacyte Announces Presentation on Investigational Human Acellular VesselTM for Treatment of Vascular Trauma at the International Committee of Military Medicine World Congress

Retrieved on: 
Friday, September 9, 2022

USAF MC), at the 44th International Committee of Military Medicine (ICMM) World Congress in Brussels, Belgium.

Key Points: 
  • USAF MC), at the 44th International Committee of Military Medicine (ICMM) World Congress in Brussels, Belgium.
  • Dr. Rasmussen added that vascular injury, whether in a military or civilian setting, is a leading cause of death and or amputation.
  • The incidence of vascular trauma in the modern combat setting has increased 5-fold over the past century.
  • Human Acellular Vessels (HAV) are investigational engineered off-the-shelf replacement vessels initially being developed for vascular repair, reconstruction and replacement.

Humacyte Presents at Multiple Conferences in September 2022

Retrieved on: 
Thursday, September 8, 2022

USAF MC) at the 44th International Committee on Military Medicine (ICMM) World Congress was given on September 7, 2022.

Key Points: 
  • USAF MC) at the 44th International Committee on Military Medicine (ICMM) World Congress was given on September 7, 2022.
  • In addition, company management will represent Humacyte at the HC Wainwright 24th Annual Global Investment Conference on September 14, 2022.
  • The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions.
  • Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications.

Humacyte Second Quarter 2022 Financial Results and Business Update

Retrieved on: 
Friday, August 12, 2022

-- Conference call and live webcast at 8:00 a.m. ET today –

Key Points: 
  • ET today
    DURHAM, N.C., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues, complex tissue systems, and organs at commercial scale, today announced financial results for the second quarter ended June 30, 2022, and highlighted recent corporate accomplishments.
  • Early in the second quarter, Humacyte launched an initiative to provide its HAVs to hospitals in Ukraine for the treatment of wounded civilians and soldiers with vascular trauma injuries.
  • Revenue was $1.3 million for the second quarter of 2022, compared to $0.7 million for the second quarter of 2021, and was $1.5 million for the six months ended June 30, 2022, compared to $0.8 million for the six months ended June 30, 2021.
  • Other net income was $55.4 million for the second quarter of 2022, compared to $2.1 million for the second quarter of 2021, and was $57.3 million for the six months ended June 30, 2022, compared to $1.5 million for the six months ended June 30, 2021.

Humacyte to Present Second Quarter 2022 Financial Results and Provide Recent Corporate Update on August 12, 2022

Retrieved on: 
Friday, August 5, 2022

A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the investors section of the Companys website for at least 30 days.

Key Points: 
  • A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the investors section of the Companys website for at least 30 days.
  • The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions.
  • Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications.
  • The HAV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.

Humacyte Preclinical Data on Small-Diameter Human Acellular Vessel™ (HAV™) in Coronary Artery Bypass Grafting (CABG) Presented at American Heart Association Meeting

Retrieved on: 
Tuesday, July 26, 2022

DURHAM, N.C., July 25, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced results evaluating the use of the small-diameter (3.5mm) Human Acellular Vessel (HAV) for coronary artery bypass grafting (CABG) in a non-human primate model. The HAV was observed to maintain structural integrity and patency for up to six months post-implantation and showed evidence of robust host cell repopulation and remodeling. The results were presented by Adam Williams, M.D., cardiothoracic surgeon, Duke University, at the American Heart Association Basic Cardiovascular Sciences Scientific Sessions (BCVS) 2022 in Chicago, IL on July 25, 2022, and will be published in the September issue of Circulation Research.

Key Points: 
  • CABG is one of the most common surgical procedures, and we are often limited by our ability to find suitable conduit.
  • In the preclinical study, CABG surgery was performed using small-diameter HAVs implanted into seven non-immunosuppressed, non-human primates following ligation of the proximal coronary artery.
  • Human Acellular Vessels (HAV) are investigational engineered off-the-shelf replacement vessels initially being developed for vascular repair, reconstruction and replacement.
  • Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications.

Humacyte Announces Presentation of Preclinical Data on the HAV™ in Coronary Artery Bypass Grafting at the Basic Cardiovascular Sciences Scientific Sessions

Retrieved on: 
Tuesday, July 19, 2022

Details of the poster presentation are as follows:

Key Points: 
  • Details of the poster presentation are as follows:
    Sponsored by the American Heart Associations Basic Cardiovascular Sciences Council, the annual BCVS Scientific Sessions is one of largest meetings in the world dedicated to fundamental and translational research to improve heart health.
  • Human Acellular Vessels (HAV) are investigational engineered off-the-shelf replacement vessels initially being developed for vascular repair, reconstruction and replacement.
  • The HAV has received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.
  • Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications.

Humacyte Announces JAMA Surgery Publication Highlighting Potential of Human Acellular Vessel™ (HAV™) to Expand Vascular Trauma Reconstruction and Bypass Treatment Options

Retrieved on: 
Wednesday, June 29, 2022

DURHAM, N.C., June 29, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that an analysis of the potential of the Human Acellular Vessel (HAV) to expand vascular surgical treatment options has been published online in the Journal of the American Medical Association (JAMA) companion journal Surgery.

Key Points: 
  • The JAMA Surgery manuscript , entitled The Human Acellular Vessel (HAV) for Vascular Reconstruction and Bypass, reviews the clinical need for improved options for vascular reconstruction and bypass conduits, and the potential advantages of the HAV over existing approaches.
  • The JAMA Surgery manuscript also highlights clinical data in support of broadly leveraging the HAV in vascular surgical contexts in the future.
  • Further study of the HAV as a long-term conduit for vascular reconstruction and bypass, in many areas where arterial bypass has limited options, is warranted.
  • Human Acellular Vessels (HAV) are investigational engineered off-the-shelf replacement vessels initially being developed for vascular repair, reconstruction and replacement.

Humacyte Expands Board of Directors with Appointment of Diane Seimetz, Ph.D.

Retrieved on: 
Monday, June 27, 2022

DURHAM, N.C., June 27, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the appointment of Diane Seimetz, Ph.D., to its board of directors.

Key Points: 
  • DURHAM, N.C., June 27, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the appointment of Diane Seimetz, Ph.D., to its board of directors.
  • Diane is an innovator and strategist with extensive experience in the biopharmaceutical industry, and we are delighted to welcome her to the Humacyte board, said Kathleen Sebelius, Chair of Humacytes board of directors.
  • Her expertise in guiding companies with innovative products to the market will be invaluable as Humacyte moves toward commercialization of the Human Acellular VesselTM (HAV).
  • Dr. Seimetz brings more than 22 years of international drug development, partnering and managerial experience in the biopharmaceutical industry to the Humacyte board.